Literature DB >> 33031085

Nitazoxanide against COVID-19 in three explorative scenarios.

José Meneses Calderón1, Ma Del Rocío Figueroa Flores2, Leopoldo Paniagua Coria3, Jesús Carlos Briones Garduño4, Jazmín Meneses Figueroa5, María José Vargas Contretas6, Lilia De la Cruz Ávila7, Salvador Díaz Meza8, Reynaldo Ramírez Chacón9, Srivatsan Padmanabhan10, Hugo Mendieta Zerón11.   

Abstract

INTRODUCTION: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting.
METHODOLOGY: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City.
RESULTS: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement.
CONCLUSIONS: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately. Copyright (c) 2020 Jose Meneses Calderon, Ma. del Rocio Figueroa Flores, Leopoldo Paniagua Coria, Jesus Carlos Briones Garduno, Jazmin Meneses Figueroa, Maria Jose Vargas Contretas, Lilia de la Cruz Avila, Salvador Diaz Meza, Reynaldo Ramirez Chacon, Srivatsan Padmanabhan, Hugo Mendieta Zeron.

Entities:  

Keywords:  SARS-CoV-2; ambulatory treatment; internal medicine; nitazoxanide; pregnancy

Mesh:

Substances:

Year:  2020        PMID: 33031085     DOI: 10.3855/jidc.13274

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

Review 1.  Potential Antiviral Strategy Exploiting Dependence of SARS-CoV-2 Replication on Lysosome-Based Pathway.

Authors:  Yungang Lan; Wenqi He; Gaili Wang; Zhenzhen Wang; Yuzhu Chen; Feng Gao; Deguang Song
Journal:  Int J Mol Sci       Date:  2022-05-31       Impact factor: 6.208

Review 2.  A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management.

Authors:  Muhammad Harris Shoaib; Farrukh Rafiq Ahmed; Muhammad Sikandar; Rabia Ismail Yousuf; Muhammad Talha Saleem
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

3.  NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown?

Authors:  Mina T Kelleni
Journal:  Inflammopharmacology       Date:  2021-11-25       Impact factor: 5.093

Review 4.  Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.

Authors:  Estefanía Calvo-Alvarez; Maria Dolci; Federica Perego; Lucia Signorini; Silvia Parapini; Sarah D'Alessandro; Luca Denti; Nicoletta Basilico; Donatella Taramelli; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2022-06-24

Review 5.  Nitazoxanide and COVID-19: A review.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Engy Elekhnawy; Gaber El-Saber Batiha
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

6.  Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital.

Authors:  Krista Yazareth Enríquez López; José Meneses Calderón; Lilia de la Cruz Ávila; Miguel Ángel López Esquivel; Jazmín Meneses Figueroa; María José Vargas Contreras; José Anaya Herrera; Ofelia Roxana Sotelo Martínez; José Antonio Mendoza López; Hugo Mendieta Zerón
Journal:  Cureus       Date:  2021-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.